News Summary

Researchers at Hamilton Health Sciences, McMaster University, and St. Joseph’s Healthcare Hamilton are pioneering a new approach in cancer treatment through the use of artificial intelligence (AI) in liquid biopsy analysis. The project, named Enhancing Liquid Biopsy Evaluation and Data Analytics for Personalized Medicine (ELEVATe-PM), aims to improve cancer detection and treatment personalization by utilizing simple blood tests to identify minimal residual disease. Funded by the Juravinski Research Institute, the initiative is led by Dr. Aly-Khan Lalani, Dr. Tobias Berg, and Dr. Darryl Leong, bringing together a team of clinicians and scientists to incorporate innovative blood testing into standard clinical practices. The research focuses initially on bladder cancer, kidney cancer, and acute myeloid leukemia, employing advanced data analytics and electronic health records to enhance treatment accuracy and speed. This project aims to position Hamilton as a leader in personalized cancer care and health data innovation.